Cargando…
Characterizing PTP4A3/PRL-3 as the Potential Prognostic Marker Gene for Liver Hepatocellular Carcinoma
BACKGROUND: A large number of cancer-related deaths in the world can be attributed to liver hepatocellular carcinoma (LIHC). The purpose of this study is to explore protein tyrosine phosphatase type IV A member 3 (PTP4A3/PRL-3) as a new and reliable biomarker to predict the prognosis of LIHC and det...
Autores principales: | Jin, Xin, Shi, Haida, Li, Zhi, Li, Huixing, Ma, Huanxian, Shi, Xianjie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546693/ https://www.ncbi.nlm.nih.gov/pubmed/36213837 http://dx.doi.org/10.1155/2022/2717056 |
Ejemplares similares
-
Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer
por: Radke, I, et al.
Publicado: (2006) -
Targeted Deletion of the Metastasis-Associated Phosphatase Ptp4a3 (PRL-3) Suppresses Murine Colon Cancer
por: Zimmerman, Mark W., et al.
Publicado: (2013) -
Upregulation of Protein Tyrosine Phosphatase Type IVA Member 3 (PTP4A3/PRL-3) is Associated with Tumor Differentiation and a Poor Prognosis in Human Hepatocellular Carcinoma
por: Mayinuer, Abudureheman, et al.
Publicado: (2012) -
PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein
por: Thura, Min, et al.
Publicado: (2019) -
Author Correction: PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein
por: Thura, Min, et al.
Publicado: (2021)